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https://doi.org/10.1016/j.devcel.2021.04.022SUMMARYRank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates
mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high
levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention
and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays
tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically,
wehave found that ectopic expressionofRankor exposure toRankl induces senescence, even in the absence
of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover,
RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into de-
layed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for
Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but
increasing tumor aggressiveness.INTRODUCTION
Cellular senescence is a potent tumor-suppressive mechanism
(Braig and Schmitt, 2006; Collins and Sedivy, 2003), induced
by stress factors such as dysfunctional telomeres, DNA damage,
and certain oncogenes (Campisi, 2003). Mutations in p53 or
p16lnk4a/pRB pathways cause resistance to senescence and
increase cancer risk (Collado and Serrano, 2005). In mice and
humans, the senescence response prevents premalignant le-
sions from progressing to malignant cancers (Krtolica et al.,
2001). But senescent cells can also act as tumor-promoting
agents (Coppé et al., 2010; Lujambio, 2016; Sun et al., 2018),
secreting factors that alter the tissue microenvironment; a
feature called senescence-associated secretory phenotype
(SASP) (Malaquin et al., 2019). The long-term exposure to senes-
cent cells is potentially detrimental, and their elimination may be
fundamental for the treatment of cancer and other diseases (ZhuDevelopmental Cell 56, 1–1
This is an open access article under the CC BY-Net al., 2016). Several senolytic drugs, such as ABT263 (navito-
clax), have been shown to preferentially kill senescent cells
with a wide range of beneficial effects (Baker et al., 2011;
Wang and Bernards, 2018; Zhu et al., 2016, 2015).
Rank and its ligand Rankl are key regulators of mammary
gland (MG) development (Fata et al., 2000; Gonzalez-Suarez
et al., 2007) and act as paracrine mediators of progesterone in
mouse (Beleut et al., 2010; Fata et al., 2000) and human mam-
mary epithelium (Tanos et al., 2013). Rank plays a dual role
during MG development since both Rank deletion and Rank
overexpression impair lactation (Fata et al., 2000; Gonzalez-
Suarez et al., 2007). Early in gestation, Rank acts as a positive
mediator of progesterone, essential for mammary epithelial cell
(MEC) proliferation, survival, and alveologenesis. However, at
mid-gestation, Rank interferes with prolactin signaling, prevent-
ing lactogenesis (Cordero et al., 2016; Fata et al., 2000; Gonza-
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tumor virus (MMTV) promoter (MMTV-Rank or Rank+/tg) impairs
MEC differentiation and leads to an expansion ofmammary stem
cells (MaSCs)—with increased ability to reconstitute the MG—
and luminal progenitors—with increased colony-forming ability
(Pellegrini et al., 2013). Multiparous Rank+/tg mice spontaneously
develop mammary adenocarcinomas containing embryonic-like
cells—dual positive for cytokeratins CK14/CK8 (Pellegrini et al.,
2013)—and show a shorter tumor latency and increased tumor
incidence compared with wild-type (WT) after carcinogenic pro-
tocols (Gonzalez-Suarez et al., 2010). Conversely, genetic or
pharmacological inhibition of Rank signaling prevents or attenu-
ates mammary tumor initiation driven by carcinogens (Gonzalez-
Suarez et al., 2010; Schramek et al., 2010).
MMTV-Neu (Neu+/) mice—which express Neu, the rat ortho-
log of human HER2 (ErbB2)—and MMTV-PyMT (PyMT+/)
mice—which express the middle T protein of the polyomavi-
rus—develop aggressive multifocal adenocarcinomas with
high incidence of lung metastasis (Muller et al., 1988; Guy
et al., 1992; Herschkowitz et al., 2007; Maglione et al., 2001).
Rank protein is expressed focally in Neu and PyMT non-trans-
formed MGs, and its levels increase in mammary preneoplastic
lesions and invasive adenocarcinomas (Gonzalez-Suarez et al.,
2010; Yoldi et al., 2016). In contrast, Rankl is expressed in pro-
gesterone-receptor-positive (PR+) cells in the non-transformed
MGs (Fernandez-Valdivia et al., 2009), but in Neu and PyMT pre-
neoplastic lesions and adenocarcinomas Rankl levels are low or
undetectable, which is in accordance with the loss of hormone
receptor expression during tumor progression (Lin et al., 2003).
We previously showed that pharmacologic or genetic loss of
Rank signaling in Neu+/ and PyMT+/ models delays tumor
onset and decreases tumor and metastasis incidence (Gonza-
lez-Suarez et al., 2010; Yoldi et al., 2016).
Here, our studies reveal that in non-transformed mammary
epithelia, Rank ectopic expression induces senescence. Rank-
driven senescence recapitulates the main characteristics of
‘‘oncogene-induced senescence’’ (Braig and Schmitt, 2006)
not only in MECs, but also in mouse embryonic fibroblasts
(MEFs): reduced proliferation, increased senescence-associ-
ated b-galactosidase (SA-b-gal) activity (Dimri et al., 1995), de-
pendency on p16/p19 tumor suppressors, DNA damage,
SASP induction, and sensitivity to senolytics. Rank-driven
senescence initially delays tumor onset in oncogene-driven
models; however, in later stages of tumor progression it pro-
motes stemness tumor growth and metastasis.
RESULTS
Ectopic Rank expression in the mammary epithelia
induces senescence and delays mammary tumor onset
Mice with ectopic MMTV-driven Rank expression, Rank+/tg
mice, develop spontaneous breast tumors, but only after multi-
ple pregnancies and with long latency (Pellegrini et al., 2013),
suggesting that additional oncogenic events may be required
for full transformation. To test this hypothesis, Rank+/tg mice
were crossed with the oncogene-driven Neu+/ or PyMT+/
mice (Neu+/Rank+/tg or PyMT+/Rank+/tg). Unexpectedly,
Rank ectopic expression delayed tumor onset driven by Neu
and PyMT oncogenes: Neu+/Rank+/tg females develop tumors2 Developmental Cell 56, 1–15, June 21, 2021later (414 ± 115 days) than Neu+/ mice (261 ± 87 days). In
PyMT+/Rank+/tg, tumor onset is also delayed (67 ± 16 days)
compared with PyMT+/ females (41 ± 7 days) (Figure 1A). More-
over, 42% of Neu+/Rank+/tg females died without tumors,
whereas all Neu+/ mice developed invasive carcinomas
(Figure 1A).
Senescence can be an efficient anti-tumormechanism (Collado
and Serrano, 2010); we thus hypothesize that high levels of Rank
may trigger senescence, delaying tumor initiation. Indeed, a clear
increase in the frequency of SA-b-gal-positive cells was found in
the hyperplasic lesions and early mammary intraepithelial
neoplasia (MIN) of Neu+/Rank+/tg and PyMT+/Rank+/tg MGs
compared with the corresponding single Neu or PyMT MGs (Fig-
ure 1B). Similar to the MGs of single Rank+/tg mice (Pellegrini
et al., 2013),multiplehyperplasiaswere found in theMGsofdouble
transgenic Neu+/Rank+/tg and PyMT+/Rank+/tg mice (Fig-
ureS1A), supporting that senescencewasprecededbyhighlypro-
liferativemammaryepithelia.Despite thehigh levelsofproliferation
found in the hyperplastic lesions, no overlap between senescence
and theproliferationmarkerKi67wasobserved, further supporting
the senescent nature of these lesions (Figure S1B).
To confirm that Rank expression could induce senescence in
mammary epithelia, non-transformed Neu+/and PyMT+/
MECs and their corresponding WT controls were infected with
Rank-overexpressing lentivirus (Figure S1C). MECs from
PyMT+/ C57Bl6 were used, since tumor onset is significantly
delayed in this background compared with FVB. The frequency
of senescent cells in control-infected MECs was similar in all ge-
notypes (10%–15%). However, a significant increase in the fre-
quency of senescent cells after Rank overexpression was
observed in Neu, PyMT, and WT MECs (Figures 1C and S1D).
These results support that Rank overexpression induces senes-
cence in the mammary epithelia, even in the absence of
additional oncogenes. Accordingly, the non-transformed and
hyperplastic epithelium of Rank+/tg MGs and their derived
cultured MECs also contained multiple senescent cells (Figures
2A, 2B, S1E, and S1F). Senescent cells were mainly located in
the luminal compartment, in hormone-receptor-negative cells,
as no co-staining of SA-b-gal with PR expression was observed
(Figure S1G). In contrast, overexpression of PyMT or Neu onco-
genes neither triggered senescence in WT MECs nor increased
senescence levels in Rank+/tg MECs (Figures S1F and S1H).
These results demonstrate that Rank signaling is a potent
inducer of senescence in the mammary epithelia.
We next asked whether stimulation of Rank signaling with
Rankl in the WT mammary epithelia with physiological levels of
Rank also induced senescence. Multiple senescent cells and hy-
perplasic structures were found in the MGs of WT mice treated
with Rankl for 14 days, recapitulating the phenotype observed
in the Rank+/tg MGs (Figure 2C). Quantification of SA-b-gal stain-
ing in cultured MECs isolated from Rankl-treated WT mice
(ex vivo) revealed senescence in 20% of the cells compared
with 3% in non-treated controls (Figure 2D). Accordingly, WT
MECs cultured with Rankl show senescence levels similar to
Rank+/tg MECs (Figures 2E and 2A). These results highlight the
physiological relevance of Rank-induced senescence and
confirm that activation of Rank signaling, either by ectopic
expression of the receptor or Rankl stimulation, promotes senes-




Figure 1. Rank overexpression in oncogenic Neu+/– and PyMT+/– backgrounds delays tumor onset and induces senescence
(A) Kinetics of palpable tumor onset with age in the indicated genotypes. Statistical difference between groups was evaluated by log-Rank test. Pie charts
represent the total frequency of mice with tumors at sacrifice. Note that some Neu+/Rank+/tg mice died or had to be sacrificed due to humane endpoints un-
related to tumor development.
(B) Representative images of H&Ewith SA-b-gal staining and quantifications (frequency of SA-b-gal-positive cells relative to total MECs) in ducts or preneoplastic
lesions of indicated age and genotype. Three representative pictures of the indicated number of MGs/mice were quantified.
(C) Frequency of SA-b-gal-positive cells in non-transformed MECs isolated from Neu+/ and PyMT+/ mice 6 days after the infection with Rank-overexpressing
(Rank) or control (f) vectors. Total number of independent experiments/MG is shown. Quantifications were performed in triplicates and each dot indicates a
replica.
(B and C) Mean, SEM and t test p values are shown. See also Figure S1.
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MEFs through p16/p19
Our data suggest that Rank overexpression leads to senescence
in MECs. Overexpression of the activated oncogene RAS
(RASV12) in MEFs constitutes the best characterized in vitro
model of OIS (Bringold and Serrano, 2000; Campisi, 2001; Ko-
dama et al., 2001; Serrano et al., 1997). Rank and RASV12
were overexpressed by viral infection in MECs and MEFs iso-
lated from WT mice and analyzed for SA-b-gal staining (Figures3A and S2A). Rank overexpression in MECs and MEFs led to the
activation of downstream pathways in the absence of Rankl (Fig-
ure S2B) and induced senescence to a similar extent than
RASV12, 35% approximately in MECs and 40% in MEFs (Fig-
ure 3A). Even low levels of Rank expression (achieved using
alternative constitutive or inducible vectors) induced senes-
cence in MECs and MEFs (Figures S2C and S2D).
Rank- and RAS-overexpressing MECs and MEFs showed





Figure 2. Rank signaling induces senescence in MECs in vivo and in vitro
(A) Representative images of H&E with SA-b-gal staining and quantifications in vivo (frequency of SA-b-gal-positive cells relative to total MECs) in MGs of the
indicated age. Three representative pictures of each MGs were quantified.
(B) Representative images of SA-b-gal staining in WT and Rank+/tg MECs cultured for 8 days and corresponding quantification ex vivo. Quantifications were
performed in triplicates and each dot indicates a replica.
(C) Representative images of H&Ewith SA-b-gal staining and quantification of in MGs fromWT females after 14 days of Rankl (n = 3) or mock in vivo treatment (n =
3). Quantifications were done in triplicates and each dot indicates a replica.
(D) Quantification of SA-b-gal staining of MECs isolated from Rankl-treated (as in C) WT females (n = 3) cultured for 8 days (ex vivo).
(E) Representative images and quantification (right panel) of SA-b-gal staining in WT MECs cultured in vitro in the presence of Rankl. Quantifications were
performed in triplicates. Each dot indicates a replica of 6 independent experiments. In all panels mean, SEM, and t test p values are shown. See also Figure S1.
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Figure 3. Rank overexpression induces senescence through p16/p19 (Ink4a/Arf) in MECs and MEFs
(A) Representative images and quantification of SA-b-gal staining in MECs isolated fromWTMGs andWT and p16/p19/MEFs 6 days after infection with Rank
or RASV12 overexpressing and control (f) vectors. Number of independent experiments is shown. Quantifications were performed in triplicates and each dot
represents a replica.
(legend continued on next page)
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Serrano, 2005), compared with control cells (Figure S2E). More-
over, an increased expression of p19 protein was detected in
Rank+/tg compared with WT-derived MECs (Figure S2F). Co-
staining of Ki67 and p19 in Rank-transduced MECs and
MEFs revealed no overlap between p19+ and Ki67+ and an in-
crease in p19+ cells compared with corresponding controls
(Figure 3B). Proliferation determined by Ki67 staining was
very low in MECs; in MEFS, the percentage of Ki67+ cells
decreased from 20% to 3% after Rank overexpression, consis-
tent with a senescent growth-arrested phenotype (Figure 3B).
Besides, neither Rank nor RASV12 were able to induce senes-
cence in MEFs in the absence of p16 and p19 (Figures 3A
and S2A).
To corroborate that Rank-induced senescence in MECs was
also mediated by p16/p19, we generated Rank+/tg p16/p19/
mice. The frequency of SA-b-gal-positive cells in the MGs from
Rank+/tg p16/p19/ was comparable with that of WT mice and
lower than in Rank+/tg MGs (Figure 3C). Quantification of SA-
b-gal staining in cultured MECs isolated from the different geno-
types corroborated these findings (Figure 3D).
Thesenescence inducedbyRASV12 isassociatedwith theacti-
vation of the DNA-damage response (Di Micco et al., 2011; Tu
et al., 2012), and DNA damagemight cause OIS (d’Adda di Faga-
gna, 2008). A significant increase in gH2AXwas found upon Rank
overexpression in MGs, MECs andMEFs compared with the cor-
respondingWTcontrols, but not inp16/p19/MEFs,which show
higherbasalgH2AX levels (Figures3E,3F,S3A,andS3B).Accord-
ingly, gH2AX+ cells were found at a similarly higher frequency in
the MGs of p16/p19/, Rank+/tg p16/p19/, and Rank+/tg
compared with WT mice (Figure 3F). Thus, Rank overexpression
induces DNA damage and senescence through p16/p19 in
MECs and MEFs.
Finally, we wondered whether, similar to activated RAS, Rank
was able to transform MEFs in the absence of p16/p19/. As
expected, in p16/p19/ MEFs, RASV12 overexpression
rapidly led to the growth of multiple colonies in soft agar,
whereas only a few and much smaller colonies grew upon
Rank overexpression (Figure S3C). These results suggest that
Rank overexpression may lead to mammary tumorigenesis in
p16/p19/ mice. The MGs of aged Rank+/tg p16/p19/
showed periductal fibrotic thickening to a greater extent than
the MGs of the single mutants Rank+/tg and p16/p19/ (Fig-
ure S3D), but no epithelial hyperplasias and/or neoplasias
were found in any of the mice analyzed. We conclude that,
although Rank and RASV12 induce similar levels of senes-
cence, Rank oncogenic potential is much lower than that of
activated RAS.(B) Representative images and quantifications of Ki67+ (green) and p19+ (red) cells
Rank-overexpressing and control (f) lentivirus.
(C) Representative images and quantification of the H&E with SA-b-gal staining in
number of MGs were quantified.
(D) Representative images and quantification of SA-b-gal staining in Rank+/tg and
performed in triplicates and each dot represents a replica of three independent M
(E) Quantification of gH2AX+ foci per nuclei in the indicated cells 6 days after inf
(F) Quantification of gH2AX+ cells relative to the epithelial area in the MGs of WT
analyzed is indicated for each genotype. Representative images are shown in Figu
S2 and S3.
6 Developmental Cell 56, 1–15, June 21, 2021Rank induces senescence in luminal cells and stemness
in basal and luminal cells
We previously found that Rank enhances stemness properties in
mouse (Pellegrini et al., 2013) and human MECs (Palafox et al.,
2012), as well as in breast cancer cells (Yoldi et al., 2016).
Rank expression leads to the counterintuitive concurrence of
stem cell properties and senescence features.
RANK expression under the MMTV promoter is predominantly
located in luminal cells (Pellegrini et al., 2013) and, accordingly,
Rank-induced senescence is restricted to the luminal compart-
ment in particular HR-negative cells (Figures 1B, 1C, and S1G).
We previously demonstrated that both Rank+/tg luminal and
basal MECs show an increased colony-forming ability compared
with the corresponding WT MECs. Moreover, Rank+/tg basal
MECs are able to regenerate MGs in limiting dilution assays
more frequently than WT basal MECs (Pellegrini et al., 2013).
Thus, while Rank-induced senescence in Rank+/tg localizes
within the MG luminal compartment, both basal and luminal
MECs show stemness features, indicating that Rank-driven
paracrine senescence mechanisms such as SASP might favor
stemness (Coppé et al., 2008; Malaquin et al., 2016). Indeed,
interrogation of the cytokine profiles of mammary epithelial
lysates revealed higher levels of proteins associated with senes-
cence such as Mmp2, Timp2, and Cxcl15 (a murine IL8 homo-
log), as well as Mmp3, bFgf, Il7, and Ccl20 (Özcan et al., 2016)
in Rank+/tg MECs compared with control cells (Figure S4A), indi-
cating that Rank overexpression induces the SASP.
To gain mechanistic insights into the ability of Rank to simulta-
neously induce stemness and senescence, RNA-seq data were
obtained from luminal and basal WT and Rank+/tg MECs. A 14-
fold increase in Rank mRNA expression was found in Rank+/tg
luminal cells, and 1,124 genes were differentially expressed be-
tween Rank+/tg and WT luminal MECs (897 up and 227 down in
Ranktg/+) (Table S1). Luminal Rank+/tg MECs have increased
expression of Cdkn2a transcripts (encoding p16/p19 proteins)
than WTs, corroborating their senescence phenotype (Table
S1). Gene set enrichment analysis (GSEA) revealed a decrease
in the luminal mature signature in Rank+/tg compared with WT
luminal MECs (Figure 4A), supportive of the stemness properties
of Rank+/tg MECs (Pellegrini et al., 2013). In accordance,
increased expression of the basalKrt14-, Pdpn-, theWnt-related
genes Rspo1 and Axin2, and reduction in the luminal differentia-
tion markers Pr, PrlR, and Csn was found in Rank+/tg luminal
MECs compared with WTs (Table S1). According to GSEA, the
signatures increased in luminal Rank+/tg were related with cell
cycle, proliferation, p53 senescence/apoptotic pathway, Rb
pathway, and DNA repair (Table S1; Figure 4A). Some of the
most prominent pathways found in luminal Rank+/tg MECswithin total nuclei (DAPI, blue) inWTMECs andMEFs 6 days after infection with
MGs of the indicated genotypes. Three representative pictures of the indicated
Rank+/tg p16/p19/ MECs (ex vivo) cultured for 8 days. Quantifications were
Gs/mice.
ection with control (f) and Rank-overexpressing virus.
, Rank+/tg, p16/p19/, and Rank+/tg p16/p19/ females. The number of mice






Figure 4. Rank-induced senescent MECs are sensitive to navitoclax and required for Rank-driven stemness
(A) GSEA graphical outputs for the association analysis between WT and Rank+/tg in luminal MECs. Each signature was analyzed using the gene subsets cor-
responding to over or underexpression (Table S1). The GSEA enrichment score and nominal p values are shown.
(B) Number of secondary mammospheres and representative images derived fromWT and Rank+/tg EpCAM+ MECs. Mean and t test p values for 5 independent
experiments are shown. For each experiment, pools of MECs from 2–3 mice were used (13 mice per genotype).
(legend continued on next page)
ll
OPEN ACCESSArticle
Developmental Cell 56, 1–15, June 21, 2021 7
Please cite this article in press as: Benı́tez et al., RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing
tumor aggressiveness, Developmental Cell (2021), https://doi.org/10.1016/j.devcel.2021.04.022
ll
OPEN ACCESS Article
Please cite this article in press as: Benı́tez et al., RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing
tumor aggressiveness, Developmental Cell (2021), https://doi.org/10.1016/j.devcel.2021.04.022include TLX-negative targets (the orphan nuclear receptor TLX
inhibits senescence and is a key regulator of stemness; O’Logh-
len et al., 2015; Wu et al., 2015; Zhang et al., 2008) and EZH2 tar-
gets, suggestive of epigenetic reprograming mechanisms
(Onder et al., 2012) (Table S1). These results corroborate that
Rank drives senescence and stemness in luminal MECs.
In the basal compartment, even though no significant differ-
ences in the expression of Rank were found between Rank+/tg
and WT MECs, 476 genes were differentially expressed, high-
lighting the relevance of the paracrine communication between
basal and luminal cells. Cdkn2a transcripts were not expressed
in Rank+/tg basal cells and, compared to WT cells, E2F and
EZH2 targets (cell cycle) were upregulated, whereas p53 and
ROS pathways, and p53 senescence targets, including Cdkn1a
(p21), were downregulated (Table S1). Moreover, in Rank+/tg
basal cells the TNF signaling pathway, recently found to restrict
basal bipotency (Centonze et al., 2020), was downregulated
(Table S1). In line with a stemness phenotype, Rank+/tg MECs
gave rise to more secondary mammospheres than WT MECs
did, confirming the increased self-renewal potential of Rank+/tg
basal cells, but no differences in mammosphere size, indicative
of proliferation, were found (Figure 4B).
Together these results support that in Rank+/tg MECs senes-
cence is restricted to the luminal compartment, whereas
increased stemness features are found in both basal and luminal
populations.
Rank-induced senescence is required for Rank-driven
stemness
Next, we tested whether Rank-induced senescence is causally
involved in the activation/acquisition of stemness properties.
To this end, we used the senolytic drug navitoclax (ABT263)
(Chang et al., 2016). In accordance with the presence of senes-
cent cells, Rank+/tg MECs are more sensitive thanWTs to navito-
clax treatment in vitro and a reduction in the frequency of SA-
b-gal positivity was observed in Rank+/tg MECs with increasing
doses of navitoclax (Figure 4C). Besides, in the presence of na-
vitoclax, the increased frequency of secondary mammosphere
formation in Rank+/tg compared with WT MECs was no longer
observed (Figure 4D).
Accordingly, senescence was not detected in the MGs of
Rank+/tg mice treated in vivo during 14 days with 25 mg/kg of na-
vitoclax (Figure 4E), and the total number of viableMECs isolated
from navitoclax-treated mice was significantly reduced in Rank+/
tg mice compared with WT (Figure S4B). SA-b-gal analysis of
culturedWT and Rank+/tg MECs isolated from navitoclax-treated
mice demonstrated comparable levels of senescent cells be-
tween genotypes (Figures 4F and S4C). Rank+/tg MGs showed(C) Percentage of surviving cells (left panel) and SA-b-gal-positive cells (right) ofW
Quantifications were performed in triplicates (each dot represents a replica) and
(D) Number of secondary mammospheres formed by WT and Rank+/tg EpCAM+
Mean, SEM, and t test p values for 4 independent experiments are shown.
(E) Representative images and quantifications (in vivo) of H&E with SA-b-gal st
representative pictures of the indicated number of MGs were quantified and mea
(F) Quantification (ex vivo) of SA-b-gal staining of WT and Rank+/tg MECs isolate
performed in triplicates and each dot represents a replica. Mean, SEM, and t tes
(G) Number of secondary mammospheres formed by WT and Rank+/tg EpCAM+
from 3 mice per genotype and treatment were pooled for each experiment. Quant
values for 2 independent experiments are shown. See also Figure S4 and Table
8 Developmental Cell 56, 1–15, June 21, 2021a reduction in the relative frequency of basal (CK5+) cells in the
epithelia and PR+ positive cells within the luminal compartment,
but navitoclax treatment did not change the luminal/basal and
HR+/HR ratios neither in WT nor in Rank+/tg MGs (Figures S4E
and S4F). Again, after in vivo treatment with navitoclax, a signif-
icant reduction in mammosphere formation ability was observed
in MECs derived from Rank+/tg but not fromWTmice. In fact, WT
and Rank+/tg MECs isolated from navitoclax-treated mice gave
rise to similar numbers of mammospheres, in contrast with those
derived from mock-treated mice (Figure 4G). These results
demonstrate that Rank-induced senescence in MECs is essen-
tial for stemness.
Rank ectopic expression increases breast cancer
stemness
Based on the results obtained in non-transformed epithelia and
previous data supporting the oncogenic role of Rank (Gonza-
lez-Suarez et al., 2010; Palafox et al., 2012; Pellegrini et al.,
2013), we hypothesized that high levels of Rank could enhance
stemness in the context of breast cancer. Indeed, despite their
delayed tumor onset, tumors in PyMT+/Rank+/tg mice grew
faster and developed more lung metastasis than single PyMT
mice developed (Figure 5A). Rank mRNA expression increases
in PyMT+/ adenocarcinomas compared with non-tumorigenic
mammary epithelia (Yoldi et al., 2016) and PyMT+/Rank+/tg tu-
mors showed even higher levels of Rank (Figure S5A). More
and larger secondary tumorspheres (Figure 5B), as well as a
significantly higher frequency of metastasis initiating cells
(MICs) (1 in 1,064 cells) was observed in PyMT+/Rank+/tg
compared with PyMT+/ MGs (1 in 6,264 cells) (Figure 5C), con-
firming that high levels of Rank increases breast cancer stem-
ness. FACS analysis revealed a significant increase in the luminal
progenitor populations CD61+ and CD49b+ cells (Oakes et al.,
2008; Shehata et al., 2012) in PyMT+/Rank+/tg compared with
PyMT+/ tumors (Figure 5D).
Mice from both genotypes developed luminal-like tumors ex-
pressing CK8 (mRNA and protein) (Figures 5E and S5A). Higher
expressionofKrt14mRNAwas found inPyMT+/Rank+/tg tumors,
and an increase in the number of CK14+ and double CK14+/CK8+
cells compared with PyMT+/ tumors was found, whereas CK5
cells were scarce in both genotypes (Figures 5E, 5F, and S5A).
These results indicate thatRankoverexpression leads toanaccu-
mulationof theembryonic-likedualpositiveCK14/CK8cells in the
PyMT tumor-prone model (Figures 5E and 5F), as previously
observed in spontaneous Rank+/tg tumors (Pellegrini et al.,
2013). Thus, Rank overexpression in the PyMT+/ mouse model
promotes the accumulation of bipotent CK14+/CK8+ MECs, an
increase in CD49b+ and CD61+ progenitor-like cells and anT and Rank+/tg MECs treated 48 h in vitrowith the indicated doses of navitoclax.
mean and SEM for 3 independent experiments are shown.
MECs after in vitro treatment with the indicated concentrations of navitoclax.
aining in WT and Rank+/tg MGs after 14 days of navitoclax treatment. Three
n and t test p values are shown.
d from navitoclax-treated mice and cultured for 8 days. Quantifications were
t p values are shown.
MECs isolated from females treated with navitoclax in vivo for 14 days. MECs









Figure 5. Rank ectopic expression increases breast cancer aggressiveness
(A) Relative tumor growth and the percentage of lungmetastasis in the indicated genotypes. Mean tumor volume ± SEM at each time point relative to their volume
on the first day of detection and statistical t test values are shown. The percentage of females with the indicated number of lung metastasis and total number of
mice is indicated.
(legend continued on next page)
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with faster growth and metastatic-initiation potential, compared
with PyMT+/ mice.
Unlike the increased frequency of senescent cells observed in
preneoplastic lesions from PyMT+/Rank+/tg compared with
PyMT+/MGs, the levels of senescence in tumor cells were com-
parable between genotypes (Figure S5B). Thus, we evaluated
whether the selective elimination of Rank-induced senescent
cells would affect tumor aggressiveness. To avoid misinterpret-
ing the effects of navitoclax on tumor cell survival, treatments
were performed before palpable lesions were detected (4–
6 weeks of age), and the mice were monitored for tumor growth.
As we are not avoiding senescence, no differences in tumor
onset were observed (Figure S5C); however, tumor growth rates
were attenuated in PyMT+/Rank+/tgmice pretreatedwith the se-
nolytic drug navitoclax comparedwith untreatedmice, indicating
that the senescent cells present in the preneoplastic lesions are
indeed favoring tumor growth (Figure 5G). Moreover, the fre-
quency of CK14/CK8-dual-positive embryonic-like cells and
CK14+ cells was reduced in PyMT+/Rank+/tg mice pretreated
with navitoclax (Figure 5F). In parallel we observed that when
PyMT tumor cells were orthotopically implanted in the MGs
from Rank+/tg and WT female littermates, 17 out of 20 tumors
(85%) grew in the senescent environment of the Rank+/tg MGs,
compared with 7 out of 18 tumors in WT glands. PyMT-derived
tumor cells also grew slightly faster in the Rank+/tg compared
with WT MGs (Figures S5D and S5E).
Together, these results demonstrate that ectopic Rank
expression enhances mammary tumor aggressiveness and sug-
gest that non-tumorigenic senescent cells support tumor growth
and stemness features.
Rank-induced senescence increases stemness in
human breast cancer cells through paracrine mediators
We next interrogated the functional consequences of overex-
pressing RANK in the human luminal breast cancer cell line
MCF7. Regardless of the levels achieved, RANK-induced senes-
cence (Figures 6A, S6A, S6B, and S6C) and increased the num-
ber of gH2AX foci per cell (Figure 6B) and the frequency of
secondary tumorspheres (Figures 6C and S6D) in MCF7 cells.
A significant reduction in MCF7 tumorsphere formation ability
was found in RANK-expressing MCF7 cells after treatment
with navitoclax (Figure 6D). Strikingly, control MCF7 cells
showed an increased frequency of secondary tumorsphere for-
mation when cultured in the conditioned media of RANK-
induced senescent MCF7 cells (Figures 6E and S6D). Together(B) Number, size and representative pictures of secondary tumorspheres derived f
independent tumors/experiments. Mean, SEM, and t test p values are shown.
(C)Metastasis initiating cell frequencies (with confidence intervals) calculated by E
shown. Cells from 2 independent tumors per genotype were pooled for injection
(D) Frequency of indicated cells in the Lin (CD45 CD31) population found in Py
Positive/negative and high/low populations were set according to cell population
(E) Representative CK14 or CK5 (green) and CK8 (red) immunostaining in PyMT
magnifications (23) to highlight CK14+/CK8+ cells. No CK5+/CK8+ cells were fo
(F) Quantification of CK8+, CK14+ and CK14+/CK8+ cells in spontaneous ade
navitoclax.
(G) Relative tumor growth curves in PyMT+/Rank+/tg mice treated or not with navit
volume on the first day of detection and statistical t test p values are shown. The
(F and G) Navitoclax treatment started (at 4 weeks) before palpable lesions were
10 Developmental Cell 56, 1–15, June 21, 2021these results confirm the functional link between senescence
and stemness in human breast cancer and denote that RANK-
induced senescent breast cancer cells enhance cancer stem-
ness through paracrine mediators.
Finally, to evaluate the clinical relevance of our findings, we
analyzed RANK protein expression during breast cancer pro-
gression in patients’ samples. RANK is expressed in a subset
of basal and luminal invasive breast adenocarcinomas, as previ-
ously reported (Palafox et al., 2012; Pfitzner et al., 2014) (Fig-
ure 6F). Importantly, high levels of RANK protein are also
detected in preneoplastic human lesions (ductal carcinoma
in situ, DCIS) from both luminal and basal-like breast cancer (Fig-
ure 6F), recapitulating the increase in RANK expression levels
found in preneoplastic MINs from Neu and PyMT-oncogene-
driven mouse models (Figure S6E).
We previously described that high levels of RANK expression
in luminal tumors from the TCGA dataset were positively corre-
lated with gene sets that characterize mammary stem cells and
luminal progenitors (Pellegrini et al., 2013). To determinewhether
RANK may also induce senescence in human breast cancer pa-
tients, we further interrogated the TCGA dataset and found an
association between high RANK expression in human breast tu-
mors from the luminal subtype and several gene sets associated
with senescence (Figure 6G; Table S2). Thus, high levels of
RANK expression are associated to senescence and stemness
in clinical breast cancer.
DISCUSSION
Despite multiple evidences supporting a pro-tumorigenic role for
RANK pathway activation, here, we reveal that ectopic expres-
sion of Rank in Neu or PyMT-oncogene-driven mouse models
promotes a delay in tumor onset and reduces tumor incidence,
as observed in loss-of-function approaches (Gonzalez-Suarez
et al., 2010; Yoldi et al., 2016). Hence, Rank loss and Rank over-
expression both delay and reduce tumor initiation through
different mechanisms. Decreased proliferation, survival, and
stemness are observed in Rank/ MECs, preventing tumori-
genesis (Fata et al., 2000; Gonzalez-Suarez et al., 2010; Yoldi
et al., 2016). Now we show that the activation of Rank signaling
leads to a potent senescence response that acts as a barrier for
tumorigenesis (Vergel and Carnero, 2014; Prieur and Peeper,
2008). Rank or RASV12 overexpression leads to senescence in
MECs andMEFs to a similar extent and sharemultiple character-
istics including induction of p16/p19, DNA damage, and SASP
(Serrano et al., 1997; Tu et al., 2012). In contrast, neither NeuromPyMT+/ and PyMT+/Rank+/tg tumor cells. Each bar represents a pool of 3
LDA, p- and chi-square values of PyMT+/ and PyMT+/Rank+/tg tumor cells are
s and metastasis were scored 8 weeks later.
MT+/ and PyMT+/Rank+/tg spontaneous tumors (n = 5–7) analyzed by FACS.
s in the normal MG. Mean, SEM, and t test p values are shown.
+/ and PyMT+/Rank+/tg spontaneous adenocarcinomas. Asterisks indicate
und.
nocarcinomas of PyMT+/ and PyMT+/Rank+/tg mice pretreated or not with
oclax for 14 days. Mean tumor volume ± SEM at each time point relative to their
number of mice is indicated.




Figure 6. RANK-driven senescence in human breast cancer cells promotes stemness by paracrine mechanisms
(A–C) Representative images and quantifications of SA-b-gal+ cells (A), gH2AX (green) foci per nuclei (DAPI, blue) (B), and size of secondary tumorspheres (C) of
MCF7 human breast cancer cells 2 weeks after infection with RANK-overexpressing (hRANK) and control (f) vectors. Quantifications for each experiment were
done in triplicates. Each dot indicates a replica. Mean, SEM, and t test p values are shown.
(D) Number of secondary tumorspheres in RANK-overexpressing (hRANK) and control (f) MCF7 cells after in vitro treatment with navitoclax.
(E) Quantification of secondary tumorspheres of control (f) and RANK-overexpressing MCF7 cells cultured in conditioned media (cm) of senescent RANK-
overexpressing MCF7 cells. All quantifications were performed in triplicates and mean, SEM, and t test p values for 3 independent experiments are shown.
(F) Representative images of RANK detection by immunohistochemistry in a subset of non-transformed breast (duct/MG), preneoplastic human lesions (ductal
carcinoma in situ, DCIS), and tumors from basal-like and luminal breast cancer.
(G) Breast cancer TCGA samples classified as luminal A or luminal B were selected and ranked by RANK expression, top and bottom 15% quantile samples were
selected as high and low rank expression, respectively. GSEA was used to perform GSEA of the described gene signatures. Genes were ranked based on
Signal2Noise metric and called significant under an FDR q value of 25%. See also Figure S6 and Table S2.
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sion in the mammary epithelia increases during aging (Pellegrini
et al., 2013) and in preneoplastic lesions (Gonzalez-Suarez et al.,
2010; Yoldi et al., 2016), and now we show that RANK is highly
expressed in human DCIS. We also demonstrate that the activa-
tion of the Rank signaling pathway, either by expression of the
receptor or treatment with the ligand, is enough to induce senes-
cence. Together, these results support a role for Rank-driven
senescence during MG development and to prevent breast can-
cer in mice and humans.
High levels of Rank in mouse and human MECs, and breast
cancer cells, interfere with differentiation resulting in an accumu-
lation of stem and progenitor cells, (Cordero et al., 2016; Gonza-
lez-Suarez et al., 2007; Palafox et al., 2012; Pellegrini et al., 2013).
Moreover, RANK overexpression enhances mammosphere- and
tumorsphere-forming ability and leads to the accumulation of
stem/progenitor populations. Rank loss in PyMT invasive carci-
nomassignificantly reduces tumorandmetastasis initiatingability
(Yoldi et al., 2016), demonstrating that Rank signaling contributes
to the maintenance of the cancer stem cell population. Accord-
ingly, double transgenic PyMT+/Rank+/tg mice show a higher
incidence of lungmetastasis. Inhibition of Rank signaling or seno-
lytic drug treatment to eliminate the senescent cells could help to
attenuate tumorprogressionormetastasis in this context. Indeed,
RANK induces senescence and stemness inMCF7 cells and high
levels of RANK expression associate with stemness (Pellegrini
et al., 2013) and senescence in human luminal breast cancer,
highlighting the relevance of our findings in the clinical setting.
The fact that Rank concomitantly increases senescence and
stemness seems contradictory; however, recent studies confirm
a link between both states, with senescent cells promoting the
occurrence of stem cells in their vicinity by paracrine mecha-
nisms (Ritschka et al., 2017). Senescent cells can enhance MEF
reprogramming through SASP (Mosteiro et al., 2018), while
senescence enhances plasticity in muscle stem cells (Chiche
et al., 2017; Ocampo et al., 2016). The reversibility of senescence
has been a subject of debate (Martı́nez-Zamudio et al., 2020).
Several studies have identified genes that allow bypassing
senescence, whereas less evidence in support of a true escape
of senescence is available (Wang et al., 2017). There is a cellular
state of light senescence, characterized by low levels of p16 that
allows cells to resume proliferation following p53 inactivation
(Beauséjour et al., 2003), different from a deep senescence state
which is irreversible. Cells in a state of senescence express a
latent adult stem cell signature and present stem cell properties
(Milanovic et al., 2018). Here, we show that Rank-induced senes-
cence is essential for Rank-driven stemness: upon elimination of
senescent cells located in the luminal compartment, the
enhanced stemness phenotype is lost. TLX and EZH2 targets
are enriched in luminal Rank+/tg MECs, suggesting that the stem-
ness/senescence phenotypes may be controlled by epigenetic
mechanisms (Franzen et al., 2016; Lee and Schmitt, 2019; Orioli
and Dellambra, 2018; Yang and Sen, 2018). Of note, multiple
genes were differentially expressed in Rank+/tg basal cells,
including downregulation of the p53 target p21, indicative of a
luminal/basal crosstalk. Functional assays from WT- and
Rank+/tg-derived MECs prove enhanced progenitor/stemness
activity on both basal (increased mammary reconstitution ability)
and luminal compartments (increased colony-forming ability)12 Developmental Cell 56, 1–15, June 21, 2021(Pellegrini et al., 2013), pointing to paracrine mechanisms regu-
lating the link between senescence and stemness upon Rank
expression. Despite the enhanced senescence observed in early
stages, tumors in PyMT+/Rank+/tg aremore aggressive, display-
ing faster tumor growth and more metastasis than PyMT+/ tu-
mors, while tumor cells derived from PyMT+/Rank+/tg mice
show increased metastasis initiating ability than PyMT+/-
derived tumor cells. Indeed, Rank+/tg mice are more susceptible
to mammary tumorigenesis driven by carcinogens and multipa-
rous females spontaneously develop mammary tumors (Gonza-
lez-Suarez et al., 2010; Pellegrini et al., 2013). These results are
in agreement with the findings describing that senescent cells
that escape senescence upon inactivation of Suv39h1 or p53
exhibit higher tumor initiation potential (Milanovic et al., 2018).
We observe no differences in tumor onset upon elimination of se-
nescent cells by navitoclax, as we are not avoiding senescence,
but tumor growth is attenuated. Moreover, increased tumor
growth is observed when PyMT tumor cells are transplanted in
the senescent environment of Rank+/tgMGs, and the senescence
conditioned media favors human breast cancer stemness.
These results suggest that senescent MECs in the vicinity of
PyMT+/Rank+/tg tumors contribute to tumor growth probably
through paracrine mediators as reported in other systems
(Coppé et al., 2010; Schosserer et al., 2017). However, we cannot
discard that tumor-cell-intrinsic mechanisms also contribute to
the faster tumor growth, metastasis, and stemness observed in
double transgenic PyMT+/Rank+/tg mice. Lineage tracing
studieswill help to determinewhether there is a direct conversion
of senescent cells into mammary stem or cancer stem cells.
Collectively, these results demonstrate that rank induces
senescence and stemness in non-transformed cells and in
breast cancer. Rank-induced senescence acts as a tumor sup-
pressor mechanism in early stages of tumorigenesis but later
increases tumor aggressiveness. Our findings point to a phys-
iological role for Rank-induced senescence and stemness dur-
ing MG development, tumor initiation, and metastasis, which
may have implications for breast cancer prevention and
treatment.
Limitations of the study
One of the limitations of our current Rank+/tg mouse models is
that Rank expression is under the MMTV promoter, which
is mainly but not exclusively expressed in luminal cells and it is
regulated by multiple factors, including hormones and even
Rankl. Moreover, since it is not feasible to isolate senescent cells
for further functional assays, we cannot determine whether
Rank-induced senescent luminal cells may hold stemness prop-
erties. Tracing strategies and superior genetic models that allow
to direct and control Rank expression specifically to basal or
luminal MECs will help to discern the particular contribution of
Rank-driven senescence within each cell compartment to stem-
ness, and in a cancer context, to tumor outcome.
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G., Sun, B., Belenki, D., Milanovic, M., Herbig, U., Schmitt, C.A., et al. (2020).
AP-1 imprints a reversible transcriptional programme of senescent cells. Nat.
Cell Biol. 22, 842–855. https://doi.org/10.1038/s41556-020-0529-5.
Meyer, K., Hodwin, B., Ramanujam, D., Engelhardt, S., and Sarikas, A. (2016).
Essential role for premature senescence of myofibroblasts in myocardial
fibrosis. J. Am. Coll. Cardiol. 67, 2018–2028. https://doi.org/10.1016/j.jacc.
2016.02.047.
Milanovic, M., Fan, D.N.Y., Belenki, D., D€abritz, J.H.M., Zhao, Z., Yu, Y., Dörr,
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doublemutant PyMT+/-Rank+/tg and Neu+/-Rank+/tg mice. p16/p19-/- mice were obtained through a collaboration withMSerrano (IRB
Barcelona) and bred with Rank+/tg mice. Given the fast tumor onset in PyMT+/- (FVB) females, PyMT+/- males are bred with Rank+/tg
female mice and after birth the pups were fed by a foster mother, as Rank+/tg females cannot lactate (Cordero et al., 2016; Gonzalez-
Suarez et al., 2007). Mice were monitored for tumor formation 3 times per week and tumors bigger than 1 cm diameter were consid-
ered as endpoint criteria for sacrifice. PyMT+/- (FVB) were backcrossed to C57Bl6 for at least 15 generations. MEFs were obtainede3 Developmental Cell 56, 1–15.e1–e7, June 21, 2021
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(C57Bl6) were used for lentiviral infections as tumor onset is delayed in this background.
Cell lines and primary cultures
MEFs were prepared essentially as described (Serrano et al., 1997). Briefly, each embryo was dispersed and trypsinized in a 10 cm
diameter plate and incubated for 2 days. At this point, most of the attached cells had the appearance of fibroblasts. These cells were
frozen in aliquots and considered passage 0 (P0). Human breast cancer MCF7 cell line was purchased from the American Type Cul-
ture Collection (Rockville, MD). ATCCprovidesmolecular authentication is support of their collection through their genomics and pro-
teomic cores by using DNA barcoding and species identification, quantitative gene expression and transcriptomic analyses. Lines
were expanded and frozen within 2 weeks of purchase and used for a maximum of 4 months after being unfrozen. Cell lines were
routinely tested for mycoplasma (Biotools, B &M Labs) and before each experiment they were confirmed to be free of contamination.
MECs were derived from adult female mice (R 8 weeks-old) as described below and were cultured in DMEM/F12, 5% FBS (Gibco),
epidermal growth factor (EGF) 100 mg/ml (Sigma), insulin 10 mg/ml (Sigma), cholera toxin 1 mg/ml and 1X Penicillin/Streptomycin
(ThermoFisher Scientific). MEFs and human breast carcinoma cells were cultured in DMEM high glucose containing 10% FBS
and 1X Penicillin/Streptomycin. All cells were incubated at 37C in 5% CO2 incubators. Primary p16/p19
-/- MEFs were provided
by M Collado. For Rankl treatments in vitro, 1 mg/ml RANKL-LZ (Amgen) was used.
Human tumor samples
Samples for immunohistochemical analysis from consented breast cancer patients were collected from the University Hospital of
Bellvitge (detailed in (Palafox et al., 2012)), using protocols approved by the IDIBELL Ethics Committee and according to Declaration
of Helsinki.
METHODS DETAILS
Rankl and Navitoclax treatments
Treatments with the Bcl-2/Bcl-xL/Bcl-w-inhibitor Navitoclax, also known as ABT-263 (Selleckchem), were performed by daily oral
gavage during 14 days at 25 mg/kg (dissolved in 15% DMSO/PEG400). Treatments with Rankl (Amgen) were performed 3 times
per week by intraperitoneal injection, during 2 weeks at 0.75 mg/kg.
MECs and mammary tumor cell isolation and orthotopic transplants
Single cells were isolated from MGs or tumors as previously described (Smalley, 2010). Briefly, fresh tissues were mechanically
dissected with McIlwain tissue chopper and enzymatically digested with appropriate medium (DMEM F-12, 0.3% collagenase A,
2.5 U/ml dispase, 20 mM HEPES, and Penicillin/Streptomycin) 45 min at 37C. Samples were washed with Leibowitz L15 medium
10% fetal bovine serum (FBS) between each step. Erythrocytes were eliminated by treating samples with hypotonic lysis buffer
(Lonza Iberica). For MEC isolation, fibroblasts were excluded by incubation with DMEM high glucose containing 10% FBS for 1
hour at 37C (the majority of fibroblasts attach to the tissue culture plate while most of the epithelial organoids do not). Single
MECs were then isolated by treating with trypsin for 2 min at 37C followed by an incubation with 2.5 U/ml dispase I (GIBCO),
20 U/ml DNaseI (Roche) for 5 min at 37C. Cell aggregates were removed by filtering the cell suspensions with 40 mm filters before
counting.
For tumor cell isolation, samples were treated with trypsin for 2 min at 37C. Cell aggregates were removed by filtering the cell
suspensionwith 70 mmfilters and 300.000 cells counted. For orthotopic transplants, tumor cells isolated fromPyMTmiceweremixed
1:1 with Matrigel matrix (BD Biosciences) and orthotopically implanted in the inguinal mammary gland of adult virgin syngeneic FVB
Rank+/tg females andWT controls. Mammary tumor growth was monitored by palpation and caliper measurement 3 times per week.
Metastasis limiting dilution assays
For limiting dilution assays, mammary tumor cells isolated from 3 primary tumors of 2 PyMT+/- and 2 PyMT-/+Rank+/tg tumor bearing
mice were pooled, resuspended in 200 ml of cold PBS and injected intravenously (tail vein) in limiting dilutions (1.000.000, 10.000,
1.000, 100 and 10 cells) in 5 weeks old Foxn1nu mice (Harlan) (4 mice per dilution). Mice were sacrificed 8 weeks after cell injection
and lungs were collected for histological analyses.
Tissue histology and immunostaining
For histological analyses, 3 mm sections from formalin fixed, paraffin embedded mammary glands were cut and stained with hema-
toxylin and eosin (H&E). Entire lungs were step-sectioned every 75/100 mm and individual metastases identified histologically based
on nuclear morphology and similarity with primary tumors.
For immunohistochemistry or immunofluorescence staining of CK5 (AF-138, Covance; 905901 Biolegend), CK8 (904801, Bio-
legend; TROMAI, obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at
The University of Iowa, Department of Biology, Iowa City, IA, USA), CK14 (AF-64, Covance), gH2AX (05-636-I, Millipore), Ki67
(12202, Cell Signaling), and PR (SP2, 12683667, Fisher), 3 mm sections from paraffin or SA-bGal embedded mammary glands
were sectioned, slides were deparaffinized and rehydrated. Antigen heat retrieval was performed with citrate buffer (pH 6) in aDevelopmental Cell 56, 1–15.e1–e7, June 21, 2021 e4
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performed pretreating sections with Protease XXIV 5 U/ml (Sigma-Aldrich) for 5min at room temperature. The antigen-antibody com-
plex was detected with streptavidin-horseradish peroxidase (Vector Laboratories) and revealed with DAB substrate (DAKO). Anti-hu-
man RANK immunohistochemistry was carried out as detailed in (Gonzalez-Suarez et al., 2010). Briefly, antigen heat retrieval was
performed with Diva Deckloader solution (Biocare Medical) and samples were blocked with avidin and biotin blocking (DAKO) in
consecutive incubations for 15 min at room temperature. Upon overnight incubation with hRANK (N-1H8, Amgen) diluted in TNB
blocking solution (Perkin Elmer), slides were incubated with biotinylated goat anti-mouse antibody (Vector Laboratories) for
30 min. For detection, Vectastin Elite ABC system (Vector) and DAB substrate (Invitrogen) were used and counterstained samples
were mounted with DPX.
For immunofluorescence of MG tissue sections, suitable fluorochrome-conjugated secondary antibodies and DAPI were added
after overnight primary antibody incubations at 4C and slides were mounted with Prolong Gold Antifade reagent (ThermoFisher
Scientific).
Senescence-associated b-galactosidase (SA-bGal) staining
Forwhole-mountSA-bGal staining,MGsand tumorswerewashed inPBS,fixed for30min (roomtemperature) in2%formaldehyde/0.2%
glutaraldehyde,washed, and incubatedovernight at37Cwith freshSA-bGal stainingsolution: 1mgof5-bromo-4-chloro-3-indolyl beta-
D-galactoside (X-Gal) perml (Apollo Scientific), 40mMcitric acid/sodiumphosphate pH5.5 (in caseof humansamplespH6), 5mMK3Fe
[CN]6, 5 mM K4Fe[CN]6, 150 mM NaCl, and 2 mM MgCl2 (Dimri et al., 1995). Stained MGs/tumors were dehydrated in ethanol and
embedded in paraffin. For SA-bGal stainingof cells in culture, cells werewashed inPBS, fixed for 15min (room temperature) in 2% form-
aldehyde/0.2% glutaraldehyde, washed and incubated overnight at 37C with fresh SA-bGal staining solution: 1 mg of X-Gal per ml
(Fisher Scientific), 40 mM citric acid/sodium phosphate pH 5.5, 5 mM K3Fe[CN]6, 5 mM K4Fe[CN]6, 150 mM NaCl, and 2 mM MgCl2.
For MCF7 cells the same protocol was used except for the 40 mM citric acid/sodium phosphate whose pH was 6.0. SA-bGal stained
mammaryglandsandcellswerephotographedonabright fieldmicroscopeand thenumberofpositivecellswasquantifiedusing ImageJ
software.
Immunofluorescence analyses
MECs, MEFs and human breast cancer MCF7 cells were seeded in eight-wells chamber slides (LabTek) with growth medium (50.000
cells/well for MECs and 25.000 cells/well for MEFs and human cell lines). After 48 hours, the medium was removed, and cells were
fixed in 2% paraformaldehyde and permeabilized using 0.5% Triton X-100 before blocking. Cells were incubated overnight at room
temperature with the primary antibodies; Ki67 (ThermoFisher Scientific), p19 ARF (5-C3-1, Santa Cruz), Anti-phospho-Histone
gH2A.X (Ser139) (Millipore) and then with Alexa-564-647 conjugated secondary antibodies (1:750; Molecular Probes) for 45 min
at room temperature and DAPI for nuclear staining. Slides were mounted with Prolong Gold Antifade Reagent (ThermoFisher Scien-
tific). Confocal analysis was carried out using a Leica confocal microscope. Images were captured using LasaF software (Leica). The
number of positive foci was quantified using ImageJ software.
Plasmid generation
Rank overexpressing plasmids were generated using Gateway cloning system strategy (Katzen, 2007) following manufacture in-
structions. The BP Reaction allows the recombination of an attB-plasmid (Rank/RANK) with an attP donor vector (pDONR 201, In-
vitrogen). Briefly, the ORFeome collaboration sequence of human or mouse RANK inserted in a pENTR223.1 vector were transferred
to the following attR destination vectors by a LR reaction: pwpi-GW (modified from the original Addgene plasmid # 12254 to insert the
gateway cassette by H Kendrick and M Smalley), psd69 (provided by M Bentires-Alj and S Duss), pLenti6/V5-DEST (Invitrogen
#V49610) or pCW57.1 (Addgene plasmid # 41393). The expression plasmids were verified by restriction enzymes and qRT-PCR an-
alyses upon cell transduction. Lentiviral vectors with promoters of different strength were used in order to drive different levels for
Rank/RANK overexpression: pwpi (EF1a, contains GFP), plenti6/V5-DEST (CMV, blasticidin selection), psd69 (PGK, puromycin se-
lection) and inducible vector pCW57.1 (puromycin selection).
In addition, the following plasmids were generously provided: (i) pEIZ-PyMT (Ma et al., 2012) (modified from the Addgene plasmid
#18121 HIV-ZSGreen) by B Welm (Huntsman Cancer Institute, UT, USA); (ii) pwpi-NeuN (pSV2) by M Smalley (Stem Cells Institute,
Cardiff, UK); and HRAS (G12V)-pcw107, modified from the original Addgene plasmid #64603, by M Collado (IDIS, Santiago de Com-
postela, Spain).
Lentivirus production and cell infection
Lentiviral infection was done following the manufacturer’s indications (Invitrogen). HEK 293T cells were transfected with lentiviral
empty, Rank or RAS overexpressing plasmids and packaging (gag-pol, vsvg, rev) plasmids (Addgene) by calcium phosphate
method. 25 mM HEPES was added 16 hours later. The virus was harvested 72 hours post-transfection, centrifugation at
1500 rpm for 5min and filteredwith 0.22 mmfilters. Non-transformedMECs,MEFs, tumor cells derived fromNeu+/- or PyMT+/- tumors
and human breast cancer cell lines were transduced in a ratio 1:4 of the virus with fresh growthmedium andwith 8 mg/ml of polybrene.
Plates were centrifuged 1 hour at 600 g at 32C to improve the infection, infected cells were selected with 5 mg/ml of blasticidin
(pLenti6/V5-DEST) or 1.5 mg/ml of puromycin (psd69, HRas (G12V)-pcw107 and the inducible vector). After selection infected cells
were maintained in 0.75 mg/ml of puromycin or 2.5 mg/ml of blasticidin.e5 Developmental Cell 56, 1–15.e1–e7, June 21, 2021
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MECs or tumor cells were isolated as described and filtered to obtain single cells. As Rank+/tg MGs contain more epithelia than WT
MGs, CD326+ (EPCAM+) cells were isolated using the EpCAM Microbeads and LS Columns (Miltenyi Biotec), to make sure that the
same number of epithelial cells was plated. 25.000 cells/ml were cultured in 2 ml of serum-free mammosphere medium DMEM/F12,
20 ng/ml of EFG, 2%B27, 1%N2, 1%P/S and 1%glutamine onto ultra-low attachment multiwell culture plates (Sigma). Mediumwas
replenished 3 times a week with or without Navitoclax (0.2 or 0.6 mM) or conditioned media. Conditioned media was collected from
RANK overexpressing MCF7 cells or controls cultured in 2D for 8 days. After 7 days, mammospheres or tumorspheres were isolated
by 5min treatment with accutase (Life Technologies) at 37C and 25.0000 cells plated for secondarymammospheres or tumorsphere
formation in triplicates. Individual spheres from each replicate well were counted under a bright field microscope and pictures were
taken for size analyses.
Soft agar colony formation assays
Infected MEFs were selected with the appropriate antibiotics and 5.000-40.000 cells were plated in a 0.6% agar upper layer over a
bottom layer of 1.2% agar in triplicates following the protocol detailed in (Borowicz et al., 2014).
RNA isolation, RT-PCR and gene expression analysis
Total RNA of frozen tumor pieces was prepared with Tripure Isolation Reagent (Roche) following the manufacturer’s instructions.
Frozen tumors tissues were fractionated using glass beads (Sigma-Aldrich) and PreCellys tissue homogenizer (Berting Technolo-
gies). cDNA was produced by reverse transcription using 1 mg of RNA following kit instructions (Applied Biosystems). Quantitative
PCR was performed using LightCycler 480 SYBR green MasterMix (Roche).
Total RNA fromMECs,MEFs, mouse and human breast cancer cells was extracted using the RNeasyMini Kit (Qiagen), sorted cells
with RNAeasy Micro kit (Qiagen) and reverse-transcribed with SuperScript II Reverse Transcriptase (ThermoFisher Scientific).
Quantitative RT-PCR (qRT-PCR) was performed using the LightCycler 480 SYBR green. Primer sequences are indicated below.
Ct analysis was performed using LightCycler 480 software (Roche).
Western blot analyses
Protein extracts were prepared with modified RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton NP-40, 0.25% sodium de-
oxycholate) containing 1x PhosSTOP and Complete protease inhibitor cocktail (Roche), and protein concentrations determined with
DC protein assay reagents (BIO-RAD). 15 mg protein were resolved by SDS-PAGE and blotted into Immobilon-P 0.45 mmmembranes
(Millipore). Antibodies against the following proteins were used for probing: Rank (R&D Systems AF692), p-p65 (#3033) and tubulin
(Abcam ab21058).
RNA sequencing
MECs were isolated as previously described; luminal (CD24hi CD49flo) and basal (CD24lo CD49fhi) cells within the Lin- population
were FACs-sorted. Raw sequencing reads in the fastq files were mapped with STAR version 2.6.1b (Dobin et al., 2013) to the Gen-
code release 17 based on the GRCm38.p6 reference genome and the corresponding GTF file. The table of counts was obtained with
FeatureCounts function in the package subread, version 1.5.(Liao et al., 2014). The differential expression gene analysis (DEG) was
assessedwith voom+limma in the limma package version 3.40.6 (Smyth, 2005) andR version 3.6.0. Genes having less than 10 counts
in at least 3 samples were excluded from the analysis. Raw library size differences between samples were treated with the weighted
‘‘trimmed mean method’’ TMM (Robinson and Oshlack, 2010) implemented in the edgeR package (Robinson et al., 2010). The
normalized counts were used in order to make unsupervised analysis, PCA and clusters. For the differential expression (DE) analysis,
read counts were converted to log2-counts-per-million (logCPM) and the mean-variance relationship was modelled with precision
weights using voom approach in limma package. RNAseq data has been submitted to GEO ID: GSE139675.
GSEA
Pre-Ranked Gene Set Enrichment Analysis (GSEA) (GSEA 2017) was used in order to retrieve functional pathways. The ranked list of
genes was generated using the -log(p.val)*signFC for each gene from the statistics obtained in the DE analysis with limma (Smyth,
2005). Functional annotation is obtained based on the enrichment of gene sets belonging to gene set collections (MSigDB 2017)
c2.all. Gene sets collected from various sources such as online pathway databases, publications in PubMed, and knowledge of
domain experts. Breast carcinomas TCGA raw counts were downloaded from UCSC Xenabrowser, lowly expressed genes across
samples and count normalization was performed using edgeR. Breast carcinomas samples classified as Luminal A or Luminal Bwere
selected and ranked by RANK expression, top and bottom 15% quantile samples were selected as High and Low RANK expression
respectively. GSEA was used to perform gene-set enrichment of the described gene signatures, genes were ranked based in Sig-
nal2Noise metric and called significant under an FDR q-value of 25%.
Mouse cytokine array
The cytokine array was performed using the Mouse Cytokine Array C100 Kit (RayBiotech) to measure the relative levels of proteins in
mammary epithelial cells lysates. The assay was performed according to the manufacturer’s instructions. Cell lysates were pooled
and an equal amount of total protein (500 mg) was loaded onto the array kit. Blot images were analyzed with ImageJ software.Developmental Cell 56, 1–15.e1–e7, June 21, 2021 e6
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Statistical analyses were performed using GraphPad Prism software. Analysis of the differences between mouse cohorts or condi-
tions was performed with a two-tailed Student’s t-test or one-way ANOVA. Two-way ANOVA was used to analyze tumor growth
curves. **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05; n.s. not significant. Estimation of tumor-initiating cells in limiting dilutions
was calculated using the extreme limiting dilution assay (ELDA) (Hu and Smyth, 2009).e7 Developmental Cell 56, 1–15.e1–e7, June 21, 2021
